nach oben

International Journal of Clinical Oncology

Erschienen in:

27.05.2021 | Original Article

High FRMD3 expression is prognostic for worse survival in rectal cancer patients treated with CCRT

verfasst von: Tzu-Ju Chen, Chia-Lin Chou, Yu-Feng Tian, Cheng-Fa Yeh, Ti-Chun Chan, Hong-Lin He, Wan-Shan Li, Hsin-Hwa Tsai, Chien-Feng Li, Hong-Yue Lai

Erschienen in: International Journal of Clinical Oncology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Rectal cancer patients can conceivably obtain relief from neoadjuvant concurrent chemoradiotherapy (CCRT) for downstaging before resection, but the stratification of risk and clinical outcomes remains challenging. Therefore, identifying effective predictive biomarkers offers clinicians the opportunity to individually tailor early interventions, which would help optimize therapy.

Methods

Using a public rectal cancer transcriptome dataset (GSE35452), we focused on cytoskeletal protein binding (GO: 0008092)-related genes and identified FERM domain containing 3 (FRMD3) as the most significant differentially expressed gene associated with CCRT resistance. We gathered 172 tumor samples from rectal cancer patients treated with neoadjuvant CCRT accompanied by curative resection and estimated the expression level of FRMD3 using immunohistochemistry.

Results

The results revealed that high FRMD3 immunoexpression was remarkably associated with advanced pre-CCRT and post-CCRT tumor status (p = 0.004 and p < 0.001), pre-CCRT and post-CCRT lymph node metastasis (both p < 0.001), more perineurial invasion (p = 0.023), and a smaller extent of tumor regression (p = 0.018). High FRMD3 immunoexpression was remarkably correlated with inferior disease-specific survival (DSS) (p = 0.0001), local recurrence-free survival (LRFS) (p = 0.0003), and metastasis-free survival (MeFS) (p = 0.0023) at the univariate level. Furthermore, in multivariate analysis, high FRMD3 immunoexpression remained independently predictive of inferior DSS (p = 0.002), LRFS (p = 0.005), and MeFS (p = 0.015).

Conclusion

These results suggest that high FRMD3 expression is related to advanced clinicopathological features and inferior therapeutic responses in rectal cancer patients treated with CCRT, validating the promising prognostic value of FRMD3 expression.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30CrossRefPubMed

Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef

Fokas E et al (2014) Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 32(15):1554–1562PubMedCrossRef

Cordes N, Meineke V (2003) Cell adhesion-mediated radioresistance (CAM-RR). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther Onkol 179(5):337–344PubMedCrossRef

Landowski TH et al (2003) Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 22(16):2417–2421PubMedCrossRef

Dickreuter E, Cordes N (2017) The cancer cell adhesion resistome: mechanisms, targeting and translational approaches. Biol Chem 398(7):721–735PubMedCrossRef

Ni X et al (2003) Molecular cloning and characterization of the protein 4.1O gene, a novel member of the protein 4.1 family with focal expression in ovary. J Hum Genet 48(2):101–106PubMedCrossRef

Buffon MP et al (2015) FRMD3 gene: its role in diabetic kidney disease. A narrative review. Diabetol Metab Syndr 7:118PubMedPubMedCentralCrossRef

Nunomura W et al (1997) Regulation of CD44-protein 4.1 interaction by Ca²⁺ and calmodulin. Implications for modulation of CD44-ankyrin interaction. J Biol Chem 272(48):30322–30328PubMedCrossRef

10.

Haase D et al (2007) FRMD3, a novel putative tumour suppressor in NSCLC. Oncogene 26(30):4464–4468PubMedCrossRef

11.

Tran YK et al (1999) A novel member of the NF2/ERM/41 superfamily with growth suppressing properties in lung cancer. Cancer Res 59(1):35–43PubMed

12.

Pezzolesi MG et al (2009) Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58(6):1403–1410PubMedPubMedCentralCrossRef

13.

Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12(1):19–23PubMedCrossRef

14.

Chan TC et al (2020) SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma. Theranostics 10(25):11775–11793PubMedPubMedCentralCrossRef

15.

Kramer-Zucker AG et al (2005) Organization of the pronephric filtration apparatus in zebrafish requires Nephrin, Podocin and the FERM domain protein Mosaic eyes. Dev Biol 285(2):316–329PubMedPubMedCentralCrossRef

16.

Freedman BI et al (2011) Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet 7(6):e1002150PubMedPubMedCentralCrossRef

17.

Al-waheeb S et al (2016) Evaluation of associations between single nucleotide polymorphisms in the FRMD3 and CARS genes and diabetic nephropathy in a Kuwaiti population. Genet Mol Res 15:114CrossRef

18.

Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767CrossRefPubMed

19.

The Cancer Genome Atlas (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407):330–7

20.

O’Donnell KA et al (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435(7043):839–843PubMedCrossRef

21.

Watanabe T et al (2014) Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Dis Colon Rectum 57(1):23–31PubMedCrossRef

22.

Murphy JM et al (2020) Targeting focal adhesion kinase in cancer cells and the tumor microenvironment. Exp Mol Med 52(6):877–886PubMedPubMedCentralCrossRef

23.

Frame MC et al (2010) The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol 11(11):802–814PubMedCrossRef

24.

Dickreuter E et al (2016) Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Oncogene 35(11):1353–1362PubMedCrossRef

25.

Vehlow A et al (2017) Adhesion- and stress-related adaptation of glioma radiochemoresistance is circumvented by β1 integrin/JNK co-targeting. Oncotarget 8(30):49224–49237PubMedPubMedCentralCrossRef

26.

Meineke V et al (2002) Ionizing radiation modulates cell surface integrin expression and adhesion of COLO-320 cells to collagen and fibronectin in vitro. Strahlenther Onkol 178(12):709–714PubMedCrossRef

27.

Bloomgarden ZT (2005) Diabetic nephropathy. Diabetes Care 28(3):745–751PubMedCrossRef

28.

Eke I et al (2012) β₁ Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest 122(4):1529–1540PubMedPubMedCentralCrossRef

29.

Ou J et al (2012) αV integrin induces multicellular radioresistance in human nasopharyngeal carcinoma via activating SAPK/JNK pathway. PLoS ONE 7(6):e38737PubMedPubMedCentralCrossRef

30.

Zeng Y et al (2015) Prognostic significance of interleukin-17 in solid tumors: a meta-analysis. Int J Clin Exp Med 8(7):10515–10536PubMedPubMedCentral

31.

Rokavec M et al (2014) IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 124(4):1853–1867PubMedPubMedCentralCrossRef

32.

Ferrao RD, Wallweber HJ, Lupardus PJ (2018) Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation. Elife 7:51CrossRef

33.

Du W et al (2012) Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway. J Cell Mol Med 16(8):1878–1888PubMedPubMedCentralCrossRef

34.

Chang L et al (2016) Cancer stem cells and signaling pathways in radioresistance. Oncotarget 7(10):11002–11017PubMedCrossRef

35.

Giancotti FG (2013) Mechanisms governing metastatic dormancy and reactivation. Cell 155(4):750–764PubMedPubMedCentralCrossRef

36.

Martini S et al (2013) From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy. Diabetes 62(7):2605–2612PubMedPubMedCentralCrossRef

37.

Fares J et al (2020) Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 5(1):28PubMedPubMedCentralCrossRef

38.

Zhou Y et al (2018) Cancer stem cells in progression of colorectal cancer. Oncotarget 9(70):33403–33415PubMedCrossRef

39.

Wang J et al (2010) Notch promotes radioresistance of glioma stem cells. Stem Cells 28(1):17–28PubMedPubMedCentral

40.

Bu P et al (2013) A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell 12(5):602–615PubMedPubMedCentralCrossRef

41.

Yahyanejad S, Theys J, Vooijs M (2016) Targeting Notch to overcome radiation resistance. Oncotarget 7(7):7610–7628PubMedCrossRef

42.

Liu WH et al (2020) CD44-associated radioresistance of glioblastoma in irradiated brain areas with optimal tumor coverage. Cancer Med 9(1):350–360PubMedCrossRef

43.

Piao LS et al (2012) CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 315(2):129–137PubMedCrossRef

44.

Dalerba P et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104(24):10158–10163PubMedPubMedCentralCrossRef

45.

Mori T et al (2008) Structural basis for CD44 recognition by ERM proteins. J Biol Chem 283(43):29602–29612PubMedPubMedCentralCrossRef

46.

Lee H et al (2020) Prominin-1-Radixin axis controls hepatic gluconeogenesis by regulating PKA activity. EMBO Rep 21(11):e49416PubMedPubMedCentral

47.

Vishnubalaji R et al (2018) Molecular profiling of ALDH1(+) colorectal cancer stem cells reveals preferential activation of MAPK, FAK, and oxidative stress pro-survival signalling pathways. Oncotarget 9(17):13551–13564PubMedPubMedCentralCrossRef

48.

Park SY et al (2019) The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. J Exp Clin Cancer Res 38(1):399PubMedPubMedCentralCrossRef

Titel: High FRMD3 expression is prognostic for worse survival in rectal cancer patients treated with CCRT
verfasst von: Tzu-Ju Chen
Chia-Lin Chou
Yu-Feng Tian
Cheng-Fa Yeh
Ti-Chun Chan
Hong-Lin He
Wan-Shan Li
Hsin-Hwa Tsai
Chien-Feng Li
Hong-Yue Lai
Publikationsdatum: 27.05.2021
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 9/2021
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-021-01944-6

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

High FRMD3 expression is prognostic for worse survival in rectal cancer patients treated with CCRT